Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
187 hedge funds and large institutions have $171M invested in Esperion Therapeutics in 2025 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 56 increasing their positions, 57 reducing their positions, and 28 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 57
2% less funds holding
Funds holding: 190 → 187 (-3)
6.7% less ownership
Funds ownership: 64.11% → 57.41% (-6.7%)
11% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 28
54% less capital inflows, than outflows
Capital inflows: $21M | Capital outflows: $45.8M
63% less call options, than puts
Call options by funds: $496K | Put options by funds: $1.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$6.69M |
| 2 |
PCM
PenderFund Capital Management
Vancouver,
British Columbia, Canada
|
+$3.69M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$2.04M |
| 4 |
TSC
Two Seas Capital
Rye,
New York
|
+$1.29M |
| 5 |
Squarepoint
New York
|
+$992K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$25M |
| 2 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
-$2.87M |
| 3 |
Goldman Sachs
New York
|
-$2.26M |
| 4 |
Two Sigma Advisers
New York
|
-$2.01M |
| 5 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$1.85M |
ESPR Hedge Fund Activity: Q1 2025 in Review
187 of the 7,478 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q1 2025, worth a combined $171M — down 38% from $278M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of ESPR and 25 opened new positions — a net loss of 3 holders — while 57 trimmed existing stakes and 56 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $6.69M. The largest seller was Wasatch Advisors, cutting an estimated $25M.
- 187 institutional investors held Esperion Therapeutics (ESPR) as of Q1 2025, down from 190 in Q4 2024.
- Funds reported $171M of Esperion Therapeutics stock for Q1 2025, down 38% quarter-over-quarter.
- 25 funds opened new Esperion Therapeutics positions in Q1 2025 and 28 closed out, a net change of -3 holders.
- The largest Esperion Therapeutics buyer in Q1 2025 was Marshall Wace, an estimated $6.69M added.
- The largest Esperion Therapeutics seller in Q1 2025 was Wasatch Advisors, an estimated $25M sold.
Based on aggregated 13F filings for Q1 2025.